Merck & Co., Inc. (NYSE:MRK) HOLD
A hold at $131.07 — a cheap, high-quality pharma compounder that has run to a 52-week high. Short-term this is a hold, and the prior short-term buy banked a win. Medium and long stay BUY. The 2028 Keytruda patent cliff is the thing to watch.
Merck has climbed to a 52-week high, and on clean earnings it is genuinely cheap. The whole debate is one number: Keytruda, its blockbuster cancer drug, loses US patent protection in 2028, and the question is whether the pipeline fills the gap.
Cheap on the earnings that matter
Merck's headline P/E looks alarming because a large one-time acquired-research charge pushed reported earnings into a loss. Strip that out and the picture flips: on clean, forward earnings it trades around 14 to 15 times — cheap for a high-quality pharma with a strong balance sheet. Valuation scores 66 and quality 68. This is not an expensive stock; it is a fairly-valued blue-chip with a specific, well-flagged overhang.
The Keytruda cliff — the whole debate
Keytruda is roughly 45 percent of Merck's drug sales, and it loses US patent exclusivity in 2028 — after which cheaper biosimilars and rival drugs compete. That is a genuine, known headwind. The bull case is that the pipeline backfills it: Winrevair is ramping fast, up around 88 percent, and a subcutaneous Keytruda plus other launches aim to defend the franchise. Analysts actually model earnings growing through the cliff. We treat it as a scored headwind, not a reason to avoid the stock — but it is the number-one thing to monitor.
Extended at the high — the short-term buy already won
On timing, the stock is at a 52-week high and the breakout came on light volume, so a fresh short-term buy needs the tape to confirm and it hasn't. That is why the short call is a hold. The prior short-term buy we flagged already worked well — it ran into the mid-teens in percentage terms, and this hold banks that win rather than chasing the same move. For a fresh entry, wait for a pullback or for the early-August earnings to clear.
What could go wrong
The balance of risk centres on the cliff. If the pipeline underdelivers, or a rival immunotherapy takes share faster than expected, the 2028 revenue gap becomes a real earnings problem and the multiple compresses toward the bear case around 108 dollars, roughly 18 percent below today. Second-quarter earnings also land in early August. Set against that is a cheap clean multiple and a defensive, cash-generative business — which is why the medium and long calls remain buys.
Risk vs Reward
Against the current US$131.07, the report frames a bull case at US$150 (+14%), a base case at US$142 (+8%) and a bear case at US$108 (-18%). See the full report for the probability weight behind each path.
The verdict
So: hold on the short term, buy on the medium and long. Merck is a cheap, high-quality pharma with a well-known 2028 overhang that the pipeline is actively working to fill. The only reason the short-term signal is a hold is the stretched entry at a 52-week high — and the prior short-term buy already captured the move. Wait for a pullback and the risk-reward improves.
That's my read on Merck. Financial Freedom. Together.
Read the full report on donatien.ca →
